Time to Invest in L...
Health Care: Drugs
Advanced Cell Tech Inc. (ACTC: OTC)
$0.07 0.00 | 0.69%
05/24/13 - 03:59 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 466.49K | 506.42K | 725.04K | 1.42M |
| Cost of Sales | 117.44K | 343.95K | 216.60K | 500.90K |
| Gross Operating Profit | 349.05K | 162.47K | 508.44K | 915.08K |
| Selling, General, and Administrative Expenses | 10.45M | 11.03M | 14.53M | 3.30M |
| Research & Development | 11.03M | 10.02M | 8.44M | 3.53M |
| Operating Income before D & A (EBITDA) | -21.14M | -20.88M | -22.46M | -5.92M |
| Depreciation & Amortization | 678.95K | 1.03M | 12.51M | 6.82M |
| Interest Income | 15.58K | 35.11K | 16.72K | 4.66K |
| Other Income - Net | -2.63M | -49.32M | -9.07M | -19.80M |
| Special Income / Charges | 0.00 | -294.14K | -11.13M | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -24.43M | -72.31M | -55.16M | -32.68M |
| Interest Expense | 4.78M | 1.51M | 11.73M | 10.90M |
| Pre-Tax Income | -29.21M | -73.82M | -66.88M | -43.58M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -28.53M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -28.53M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -28.53M | -72.80M | -54.37M | -36.76M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-28.53M | 294.14K | 11.13M | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -28.53M | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -0.01 | -0.05 | -0.04 | -0.07 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.01 | -0.05 | -0.04 | -0.07 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.01 | -0.05 | -0.04 | -0.07 |
| Basic Normalized Net Income/Share | -0.01 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -0.01 | -0.05 | -0.04 | -0.07 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.01 | -0.05 | -0.04 | -0.07 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.01 | -0.05 | -0.04 | -0.07 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.01 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ACTC
- Portfolio NameUser Type
- UserKJ Stocks
- UserMark
- UserBiotech88
- UserThe Jayden Project
- Userwright stocks
- UserRimp's Stockpicks
- UserMy Portfolio
- User2
- User1
- UserRAPTOR LAST 2
Latest ACTC Headlines from TheStreet
- Thursday's Small-Cap Winners & Losers 06.21.07 | 04:06 pm
Press Releases for ACTC
- Advanced Cell Technology, Cytomedix And Mesoblast To Provide Corporate And Clinical Updates At Regen Med Investor Day - PR Newswire 04.09.13 | 12:04 pm
- ACT’s Chief Scientific Officer Dr. Robert Lanza To Deliver The Nerem Lecture 2013 At The 17th Annual Hilton Head Workshop - Business Wire 03.22.13 | 08:03 am
- Advanced Cell Technology Receives Approval From Data Safety Monitoring Board (DSMB) To Initiate Treatment Of Third Patient Cohort In All Three Clinical Trials - Business Wire 03.14.13 | 08:03 am
- ACT’s Dr. Robert Lanza Voted Top 4 “Most Influential People On Stem Cells” - Business Wire 03.12.13 | 08:03 am
- Advanced Cell Technology To Present At BIO-Europe Spring 2013 - Business Wire 03.08.13 | 12:03 pm
- Advanced Cell Technology Announces Fourth-Quarter And Year-end Results - Business Wire 03.07.13 | 04:03 pm
- Advanced Cell Technology To Announce Fourth Quarter And Year-end Results On Thursday March 7th - Business Wire 03.04.13 | 09:03 am
- ACT’s Chief Scientific Officer Robert Lanza, MD, Appointed Editor-in-Chief Of BioResearch Open Access Journal - Business Wire 02.11.13 | 11:02 am
- ACT’s Clinical Partner Receives FDA Approval To Initiate Clinical Trial Using The Company’s HESC-derived Cells To Treat Severe Myopia - Business Wire 02.11.13 | 08:02 am
- Advanced Cell Technology To Present At 15th Annual BIO CEO & Investor Conference - Business Wire 02.08.13 | 08:02 am
Partner Headlines for ACTC
- First patients picked for stem cell vision trials - Reuters 06.16.11 | 09:06 am
- UPDATE 3-US court backs federal embryonic stem cells funds - Reuters 04.29.11 | 02:04 pm
- FDA OKs second Advanced Cell stem cell trial - Reuters 01.03.11 | 11:01 am
- UPDATE 2-Second US company gets stem cell go-ahead - Reuters 11.22.10 | 02:11 pm
- UPDATE 3-First patient treated in Geron stem cell trial - Reuters 10.11.10 | 03:10 pm
- Geron given FDA go-ahead for stem cells trial - Financial Times 07.30.10 | 06:07 pm
